Avita Medical, INC

AVITA Medical has officially appointed interim leader Cary Vance as President and CEO, while naming Jan Stern Reed as Chair of the Board.

AVITA Medical announced its full year 2025 financial results, reporting 11% revenue growth and a significant reduction in net loss, alongside a strategic debt refinancing.

AVITA Medical refinanced its debt with a new $60 million credit facility from Perceptive Advisors and provided an update on its 2025 revenue and 2026 guidance.

AVITA Medical, a leading acute wound care company, announced the appointment of seasoned healthcare executive Joe Woody to its Board of Directors, effective January 1, 2026, alongside the retirement of former Chairman Lou Panaccio.

AVITA Medical reported a 13% decrease in Q3 2025 commercial revenue to $17.1 million, revised its full-year outlook, and amended its credit agreement with OrbiMed.

AVITA Medical announced the departure of CEO James Corbett, appointing Chairman Cary Vance as Interim CEO, and reported preliminary third-quarter revenue of approximately $17 million.

AVITA Medical's Q1 2026 filing details revenue growth, operational expense reduction, and a new $60 million credit facility, while acknowledging ongoing going concern doubts.

AVITA Medical reported a 19% reduction in net loss for Q3 2025, despite a 13% revenue decline, driven by cost savings and new product launches, while facing ongoing debt covenant challenges and a CEO transition.

AVITA Medical, Inc. reported a 21% increase in Q2 2025 revenue and a 36% reduction in net loss, but faces substantial doubt about its ability to continue as a going concern due to debt covenant non-compliance and liquidity challenges.

Avita Medical obtained a waiver for a trailing 12-month revenue covenant while reporting a 67% increase in total revenues for the first quarter of 2025.

Avita Medical saw a significant increase in revenue during the third quarter of 2024, but also experienced a widening net loss compared to the same period last year.

AVITA Medical's second quarter results show a significant revenue increase driven by deeper market penetration and new customer acquisitions for their RECELL technology.

AVITA Medical reports an 11% revenue increase to $71.6 million in 2025, refinances its debt with a new $60 million credit facility, and expands its acute wound care product portfolio with new regulatory approvals and clinical studies.

AVITA Medical's 2024 10-K filing reveals a 28% increase in total revenue driven by deeper market penetration and new product offerings, alongside strategic efforts to achieve profitability and expand global reach.

Avita Medical secures a waiver and amendment to its credit agreement, files its annual report on Form 10-K, and provides updates on its product pipeline and financial performance.

CFO David O'Toole acquired 2,000 shares of AVITA Medical common stock at a price of $3.97 per share.

Director Woody Fralin acquired 5,200 shares of AVITA Medical common stock in an open market transaction.

Director Woody Fralin purchased 10,000 shares of AVITA Medical common stock in open market transactions.

Director Woody Fralin purchased 10,000 shares of AVITA Medical common stock in two separate transactions on June 3, 2026.

Director Robert McNamara received restricted stock units and stock options following shareholder approval.

Director Woody Joseph Fralin reports the acquisition of restricted stock units and stock options following shareholder approval.

AVITA Medical is holding its 2025 Annual Meeting of Stockholders on June 4, 2025, to vote on director elections, auditor ratification, executive compensation, and approval of equity incentive plans.

AVITA Medical will hold its annual stockholders meeting virtually on June 5, 2024, to vote on director elections, auditor ratification, equity grants, and executive compensation.

The Vanguard Group filed an amended Schedule 13G, reporting a 4.73% beneficial ownership in Avita Medical Inc. common stock as of December 31, 2025, following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.3% beneficial ownership stake in AVITA Medical, Inc. as of September 30, 2025.